Skip to main content

Akari Therapeutics Plc

For the period ended Jun 30, 2024. Filed Aug 19, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 19, 2024

AKTX$7.66+3.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

June 30,December 31,
(In thousands, except share and per share amounts)20242023*
ASSETS
Current assets:
Cash$4,177$3,845
Prepaid expenses805299
Other current assets94197
Total current assets5,0764,341
Patent acquisition costs, net—14
Total assets$5,076$4,355
LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities:
Accounts payable$4,686$1,671
Accrued expenses1,6851,566
Convertible notes, related party1,000—
Warrant liability7551,253
Other current liabilities65394
Total current liabilities8,7794,584
Commitments and contingencies (Note 9)
Shareholders’ deficit:
Share capital of $0.0001 par value
Authorized: 45,122,321,523 ordinary shares at June 30, 2024 and December 31, 2023, respectively; issued and outstanding: 24,289,232,698 and 13,234,315,298 at June 30, 2024 and December 31, 2023, respectively2,4301,324
Additional paid-in capital183,007174,754
Capital redemption reserve52,19452,194
Accumulated other comprehensive loss(749)(1,040)
Accumulated deficit(240,585)(227,461)
Total shareholders’ deficit(3,703)(229)
Total liabilities and shareholders' deficit$5,076$4,355

———————

  • The condensed balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.